DEF 14A: International Stem Cell Corporation Sets Date for Virtual Annual Stockholders Meeting

International Stem Cell Corporation will hold its annual meeting of stockholders virtually on June 11, 2024, to elect directors and transact other business.

Summary

• International Stem Cell Corporation (ISCO) will hold its annual meeting of stockholders on June 11, 2024, at 10:00 a.m. Pacific Time, as a virtual meeting.
• The meeting will include the election of four directors, two of whom will be elected by holders of Series D Preferred Stock.
• Stockholders of record as of April 15, 2024, are entitled to vote.
• To participate virtually, stockholders must register in advance at www.proxydocs.com/ISCO by June 7, 2024, at 5:00 p.m. Eastern Time.
• The board of directors recommends voting for each of the director nominees.
• The company's Board of Directors consists of four directors who serve one-year terms.
• The company's independent registered public accounting firm is BDO USA, P.C.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive sentiment due to the forward-looking statements about reviewing activities and plans for the future. The inclusion of independent directors and adherence to corporate governance standards also contribute to a positive impression.

Positives

• The Board of Directors includes two independent members, Paul Maier and Donald Wright, who meet Nasdaq independence requirements.
• The Audit Committee and Compensation and Governance Committee are composed of independent directors.
• The company has a Code of Conduct and Ethics applicable to all employees, officers, and directors.
• The Audit Committee has a written charter available on the company's website.
• The Compensation and Governance Committee will consider qualified director candidates suggested by stockholders.

Negatives

• The company is considered a smaller reporting company, which means it has less extensive disclosure requirements for executive compensation.
• The company did not match employee contributions to the 401(k) plan.
• The company reported a net loss of $(131,000) in 2023 and $(331,000) in 2022.

Risks

• The proxy statement notes that brokers may not vote shares held in street name on non-routine matters, such as the election of directors, if they have not received voting instructions from the beneficial owner.
• The company's success depends on attracting, retaining, and rewarding key employees.
• The company's risk exposure is overseen by the Board, with each committee focusing on risk areas associated with its responsibilities.

Future Outlook

At the annual meeting, the company will review its activities over the past year and its plans for the future.

Management Comments

• Andrey Semechkin, PhD, Chief Executive Officer and Co-Chairman, stated that the Board of Directors and management look forward to stockholder participation at the annual meeting.
• The Board of Directors unanimously recommends a vote for each of the director nominees.

Industry Context

As a stem cell company, ISCO operates in the biotechnology and pharmaceutical industries, which are characterized by high research and development costs, regulatory scrutiny, and competition from other companies developing similar therapies.

Comparison to Industry Standards

• Executive compensation practices are generally aligned with smaller reporting companies, focusing on base salary and long-term equity incentives.
• The company's corporate governance practices, such as having independent directors and audit and compensation committees, are consistent with Nasdaq listing requirements.
• The company's audit fees appear reasonable compared to other similarly sized companies in the biotechnology industry.

Related Party Transactions

• On January 13, 2022 to obtain additional funding for working capital purposes we issued an unsecured, non-convertible promissory note in the principal amount of $2,900,000 (the Note) to Dr. Andrey Semechkin, our CEO.
• On March 1, 2022, the Company and Dr. Andrey Semechkin, the Companys Chief Executive Officer, agreed to extend the maturity date of the Note for an additional six-month period to September 15, 2022.
• On September 15, 2022, Dr. Semechkin surrendered the Note and the Company issued Dr. Semechkin a promissory note in the amount of $2,900,000 (the New Note), which featured the same terms as the previously outstanding note, with the exception of an extension of the maturity date from September 15, 2022 to March 15, 2023.
• On March 14, 2023, the Company and Dr. Andrey Semechkin, the Companys Chief Executive Officer, agreed to extend the maturity date of the New Note for an additional six-month period to September 15, 2023.
• On September 15, 2023, Dr. Semechkin surrendered the New Note and the Company issued Dr. Semechkin a promissory note in the amount of $2,900,000, which featured the same terms as the previously outstanding note, with the exception of an extension of the maturity date from September 15, 2023 to September 15, 2024.
• In October 2021, we and S Real Estate Holdings, LLC jointly entered into a lease agreement with Rehco Holdings, LLC, for the purpose of establishing a new corporate headquarters, including corporate, R&D, and manufacturing operations.
• S Real Estate Holdings LLC is owned by Dr. Russel Kern, the Companys Executive Vice President and Chief Scientific Officer.
• The Lease was personally guaranteed by Dr. Russell Kern.
• In December 2021, we and S Real Estate Holdings LLC entered into a co-tenant agreement, whereby we and S Real Estate Holdings LLC agreed to allocate portions of the base rent and variable charges, including insurance, maintenance costs, taxes and operating expenses, between the parties.
• During the term of the Lease, we will be liable for 40% of all costs incurred in connection with the Lease, while S Real Estate Holdings LLC will be liable for the remaining 60%.
• During the year ended December 31, 2023, we made payments totaling $80,867 under this lease representing our portion of the costs allocated to the Company.

Stakeholder Impact

• Shareholders are encouraged to participate in the annual meeting and vote on important matters.
• Employees are subject to the company's Code of Conduct and Ethics.
• The company's performance and future plans may impact stakeholders such as customers, suppliers, and creditors.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• Stockholders who wish to attend the virtual annual meeting must register in advance.
• The company will file a Form 8-K report with the SEC to report the final voting results within four business days of the Annual Meeting.

Key Dates

Keywords

annual meeting, stockholders, directors, proxy statement, corporate governance, executive compensation, voting, ISCO, International Stem Cell Corporation